Lakewood-Amedex lines up October conference appearances

Lakewood-Amedex Biotherapeutics said CEO Kelvin Cooper will take part in three industry conferences in New York City and Washington, D.C., in mid-October. The appearances give the clinical-stage biotech a platform to discuss its Bisphosphocin antimicrobial program and Nu-3 preclinical data with investors and infectious disease experts.

Why it matters: - Lakewood-Amedex Biotherapeutics is using three October conferences to put its antimicrobial pipeline in front of investors, biotech specialists and infectious disease researchers. - The events give the clinical-stage company a public venue to discuss Bisphosphocin® development and Nu-3 preclinical data.

What happened: - Lakewood-Amedex Biotherapeutics said CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences. - Cooper is scheduled to attend the Maxim Growth Summit on Oct. 14, 2026, in New York City. - Cooper will also attend and present at the ThinkEquity Conference on Oct. 15, 2026, in New York City. - Cooper will present a poster on Nu-3 preclinical data at IDWeek on Oct. 22, 2026, in Washington, D.C.

The details: - The Maxim Growth Summit runs Oct. 13-14, 2026, at the Hard Rock Hotel in New York City. - The ThinkEquity Conference runs Oct. 15, 2026, at The Mandarin Oriental Hotel in New York City. - Cooper’s ThinkEquity presentation is titled, “Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers.” - The ThinkEquity presentation is scheduled for 3:30 p.m. - IDWeek runs Oct. 21-24, 2026, at the Walter E. Washington Convention Center in Washington, D.C. - IDWeek will offer a hybrid format. - Lakewood-Amedex said the conferences will help the company engage with the investment, biotechnology and infectious disease communities. - The company said the events will also highlight ongoing development programs for its Bisphosphocin® antimicrobial technology. - Lakewood-Amedex is a clinical-stage biotechnology company developing fast-acting, broad-spectrum antimicrobials aimed at treating infectious diseases and reducing antibiotic-resistant bacterial strains, including MRSA and VRE. - The company is a B2i Digital Featured Company, with an in-depth profile available here. - More information is available on the company's website at https://lakewoodamedex.com.

Between the lines: - The conference schedule suggests Lakewood-Amedex is trying to build visibility around both its investor story and its scientific pipeline at the same time. - The poster at IDWeek could be especially relevant because infectious disease specialists may focus more on preclinical efficacy data than general capital-markets audiences.

What's next: - Cooper will appear at the three events across Oct. 14-22, 2026. - Investors and researchers will be watching for any new detail on Nu-3 and the broader Bisphosphocin program during the presentations.